High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab

[1]  T. Witzig,et al.  Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma , 2014, Haematologica.

[2]  J. Tuscano,et al.  Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook , 2013, BioDrugs.

[3]  F. Forrer,et al.  Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab. , 2012, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[4]  P. Parren,et al.  Crosstalk between Human IgG Isotypes and Murine Effector Cells , 2012, The Journal of Immunology.

[5]  A. Scott,et al.  Radioimmunotherapy of Fibroblast Activation Protein Positive Tumors by Rapidly Internalizing Antibodies , 2012, Clinical Cancer Research.

[6]  Chien-Hsing Chang,et al.  The Dock-and-Lock (DNL) Approach to Novel Bispecific Antibodies , 2011 .

[7]  D. Huglo,et al.  High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Belizário.  Immunodeficient Mouse Models: An Overview , 2009 .

[9]  D. Goldenberg,et al.  A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. , 2009, Blood.

[10]  F. Forrer,et al.  In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  D. Greiner,et al.  Non‐obese diabetic–recombination activating gene‐1 (NOD–Rag 1 null) interleukin (IL)‐2 receptor common gamma chain (IL 2 rγnull) null mice: a radioresistant model for human lymphohaematopoietic engraftment , 2008, Clinical and experimental immunology.

[12]  M. Czuczman,et al.  Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab) , 2008, Clinical Cancer Research.

[13]  Ø. Bruland,et al.  Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate , 2007 .

[14]  J. Pagel,et al.  Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. , 2007, Cancer research.

[15]  A. Wu,et al.  Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. , 2007, Cancer research.

[16]  Wen-yu Li,et al.  CHOP-Like Chemotherapy Plus Rituximab Versus CHOP-Like Chemotherapy Alone in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma:A Randomised Controlled Trial by the MabThera International Trial (MInT) Group , 2007 .

[17]  Ø. Bruland,et al.  Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate. , 2007, Blood.

[18]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[19]  M. Brechbiel,et al.  Radioimmunotherapy of CD22-Expressing Daudi Tumors in Nude Mice with a 90Y-Labeled Anti-CD22 Monoclonal Antibody , 2005, Clinical Cancer Research.

[20]  R. Gascoyne,et al.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Goldenberg,et al.  177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo. , 2005, Nuclear medicine and biology.

[23]  S. Horning,et al.  Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Goldenberg,et al.  Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  U. Haberkorn,et al.  Conjugation of DOTA using isolated phenolic active esters: the labeling and biodistribution of albumin as blood pool marker. , 2005, Bioconjugate chemistry.

[26]  A. Zelenetz,et al.  The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy , 2004, Clinical Cancer Research.

[27]  M. Brechbiel,et al.  Antibody-targeted radiation cancer therapy , 2004, Nature Reviews Drug Discovery.

[28]  Mitchell R. Smith.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance , 2003, Oncogene.

[29]  Andrew C. R. Martin,et al.  Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment. , 2003, Protein engineering.

[30]  W. Oyen,et al.  Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma. , 2003, Cancer biotherapy & radiopharmaceuticals.

[31]  E. Cavallin-ståhl,et al.  A Systematic Overview of Radiation Therapy Effects in Non-Hodgkin's Lymphoma , 2003, Acta oncologica.

[32]  L. Gordon,et al.  Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  L. Chappell,et al.  In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. , 2002, Nuclear medicine and biology.

[35]  Damon L. Meyer,et al.  A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. , 2001, Blood.

[36]  G. Griffiths,et al.  Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  D. Goldenberg,et al.  Single-cell cytotoxicity with radiolabeled antibodies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  A. Børresen-Dale,et al.  Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in b‐cell non‐Hodgkin's lymphoma , 2000, International journal of cancer.

[39]  M. Brechbiel,et al.  Evaluation of methods for large scale preparation of antibody ligand conjugates. , 1999, Nuclear medicine and biology.

[40]  M. Juweid,et al.  Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22 , 1997, Cancer Immunology, Immunotherapy.

[41]  I. Pastan,et al.  Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies. , 1996, Bioconjugate chemistry.

[42]  A S Dion,et al.  Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. , 1995, Molecular immunology.

[43]  S. Steinberg,et al.  Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. , 1995, Blood.

[44]  K. Kohn,et al.  p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. , 1994, Cancer research.

[45]  K. Kohn,et al.  Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. , 1993, Cancer research.

[46]  Felix Franks,et al.  In-Vitro Characterization of mCerulean3_mRuby3 as a Novel FRET Pair with Favorable Bleed-Through Characteristics , 2019, Biosensors.

[47]  R. Collins,et al.  Phase I immunotoxin trial in patients with B-cell lymphoma. , 1991, Cancer research.

[48]  A. Giaccia,et al.  scid mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[49]  R. Wahl,et al.  Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  S. Mirzadeh,et al.  Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. , 1990, Bioconjugate chemistry.

[51]  N. Tamaoki,et al.  In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. , 1981, Journal of immunology.